Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 18, 2025Bone Marrow TransplantationOpen Access

Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAmandeep SalhotraDYDongyun YangMMMonzr M. Al Malki

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved overall survival in older patients with AML receiving flu/mel and tac/sir GVHD prophylaxis.

Key Points

  • Evaluate long-term survival outcomes of allo-HCT in AML with flu/mel conditioning and tac/sir GVHD prophylaxis.
  • Single-center retrospective analysis
  • Patients with AML who underwent allo-HCT (n = 342)
  • Data collected from 2008-2019 at City of Hope
  • Five-year overall survival was 55% among all patients
  • 70% overall survival in patients aged ≥70
  • Five-year non-relapse mortality was 24% overall
  • Active disease correlated with lower overall survival (HR = 1.95; p < .001)

Cite This Study

Salhotra et al. (2025) studied this question.

synapsesocial.com/papers/6924fef4c0ce034ddc351d09https://doi.org/10.1038/s41409-025-02738-4
View Full Paper
Ask AI
Bookmark
Share